Despite limited data, panel-based sequencing approaches have entered into clinical practice for gastric cancer allowing for simultaneous determination of actionable biomarkers including microsatellite instability (MSI) and expression of HER2 and PD-L1 to guide approved biologic therapies. This evidence concerns the gene ERBB2 and gastric cancer.